Long-term results of frontline dasatinib in chronic myeloid leukemia.
Abhishek MaitiJorge E CortesKeyur P PatelLucia MasarovaGautam BorthakurFarhad RavandiSrdan VerstovsekAlessandra FerrajoliZeev EstrovGuillermo Garcia ManeroTapan Mahendra KadiaGraciela M Nogueras-GonzálezJeffrey SkinnerRebecca PokuSara DellaSalaRajyalakshmi LuthraElias J JabbourSusan O'BrienHagop M KantarjianPublished in: Cancer (2020)
After this long-term follow-up, dasatinib continues to show an excellent safety profile and produces rapid cytogenetic responses and MRs, durable deep MRs, and excellent long-term survival outcomes in patients with chronic-phase chronic myeloid leukemia.